How estrogen affects immune responses in head and neck cancer
Sexual dimorphism and the immuno-modulatory role of estrogen signaling in HNSCC
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11250398
This study is looking at how estrogen affects the immune system's response to treatment in patients with head and neck cancer, especially focusing on why premenopausal women seem to do better with immunotherapy, with the goal of finding new ways to improve treatment for everyone.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11250398 on ClinicalTrials.gov |
What this research studies
This research investigates the role of estrogen signaling in head and neck squamous cell carcinoma (HNSCC), particularly focusing on how it influences the immune response to treatment. It examines the differences in treatment responses between male and female patients, especially premenopausal women, who appear to respond better to immunotherapy. The study utilizes clinical trial data and preclinical models to explore how estrogen impacts immune cell behavior and the tumor microenvironment, aiming to uncover mechanisms that could improve treatment outcomes for patients. By understanding these dynamics, the research seeks to identify potential therapeutic strategies that leverage estrogen's immuno-modulatory effects.
Who could benefit from this research
Good fit: Ideal candidates for this research include premenopausal women diagnosed with head and neck cancer who are undergoing or considering immunotherapy.
Not a fit: Patients who are postmenopausal or male may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for patients with head and neck cancer, particularly benefiting premenopausal women.
How similar studies have performed: Other research has indicated that hormonal influences can significantly affect cancer treatment responses, suggesting that this approach may yield valuable insights.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KARAM, SANA D — WASHINGTON UNIVERSITY
- Study coordinator: KARAM, SANA D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.